PepGen CEO Makes Major Stock Purchase Amid Clinical Developments James McArthur, President and CEO of PepGen, recently acquired 41,500 shares, signaling confidence in the company as it navigates clinical trial updates and leadership changes. The purchase follows a temporary pause in a key Duchenne muscular dystrophy study and the resignation of the Chief Medical Officer, with analysts maintaining positive ratings despite ongoing challenges.123